
#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 12 months ago Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement
Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]
Posted 2 years ago Tagged abuse of dominance Article 101 Article 102 French Competition Authority French competition law pharmaceutical product denigration
At its most basic, marketing often consists of simply explaining a product’s qualities relative to […]
Posted 3 years ago Tagged antitrust class action competition drug intellectual property IP litigation patent pharmaceutical price product settlement
Battles in the pharmaceutical antitrust world have been increasingly heated, and to a great extent […]